Galapagos advances AbbVie-partnered CF drug; UCL forms £50M fund; Vasopharm bags €20M

Nick Paul Taylor

In this week's EuroBiotech Report, the first of two correctors destined for use in ' triple-hit cystic fibrosis therapy is now in the clinic. With as many as four more assets due to enter Phase I before 2016 is over, thinks it has the credentials to call the franchise a full-sized portfolio. And more.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS